[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649333":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":41,"collaborators":44,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":81,"overallStatus":98,"whyStopped":10,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Ahmadu Bello University","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Training and Supported risk assessment",null,[12],"Other: (a) Training and (b) Supported risk assessment",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"(a) Training and (b) Supported risk assessment","1. The training intervention will be facilitated by experienced clinical mentors through didactics and demonstrations and conducted as half-day sessions over 3 days\n2. This intervention includes risk calculator use and clinical mentorship for at least six months.",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Musliu Adetola TOLANI, MBBS PGCertPH ChM FWACS FMCS","CONTACT","+2348035646382","adetolatolani@yahoo.com",[25],{"facility":26,"status":10,"city":27,"state":28,"zip":10,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Ahmadu Bello University Teaching Hospital","Zaria","Kaduna State","Nigeria","NG",{"type":32,"coordinates":33},"Point",[34,35],7.7227,11.11128,{"lat":35,"lon":34},[38,39],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},{"name":20,"role":40,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":40,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Musliu Adetola Tolani","Senior Lecturer",[45],{"name":46,"class":47},"Fogarty International Center of the National Institute of Health","NIH","100649333","prostate-cancer-risk-calculator-for-actionable-clinical-decision-making-in-nigeria-100649333",false,"NCT07733440","PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria","Clinical Risk Calculator Validation and Implementation to Optimize Prostate Cancer Early Detection in Nigeria","PROACT","Inclusion Criteria:\n\n1. Training - Eligible primary care providers (for the training surveys) will be healthcare practitioners at community-level hospitals.\n2. Supported Risk Assessment\n\n(i) Eligible key informants will be eligible primary care providers who were trained and implemented the supported risk assessment and the targeted population of patient participants who received the supported risk assessment.\n\n(ii) Eligible patient participants (for the collection of observation data) will be the target population of adult males 40 - 79 years accessing provider services.\n\nExclusion Criteria:\n\n\\-",true,"MALE","18 Years",{"count":60,"type":61},89,"ESTIMATED","INTERVENTIONAL",[64],"NA","This study is a pilot trial that builds on findings from the validation of prostate cancer risk calculators in Nigerian men. The goal of the overall study is to improve the early detection of prostate cancer in a high-risk population.\n\nThe main questions the validation study aims to answer are:\n\n1. How accurately do existing prostate cancer risk calculators identify Nigerian men with clinically significant prostate cancer?\n2. Will a new risk calculator designed for Nigerian men more accurately identify those with clinically significant prostate cancer?\n\nThe main questions the intervention study aims to answer is:\n\nWill the primary care provider-facing risk calculator be feasible and acceptable for primary care providers to implement?\n\nThe intervention trial will be piloted among participants in community-level hospitals in order to primarily assess implementation outcomes",[67,68,69,70,71,72,73,74,75,76,77,78,79,80,29],"Prostate Cancer","Risk Assessment","Clinical Decision Support Systems","Predictive Value of Tests","Models","Algorithms","Evidence-Based Practice","Implementation Research","Community Health Services","Primary Health Care","Biomarker","Prostate Specific Antigen","Global Health","Africa",[82,83,84,85,86,87,88,89,90,91,92,93,80,94,95,96,97,29],"Prostate cancer","early detection","prostate cancer screening","early diagnosis","prostate specific antigen","risk calculator","risk prediction model","diagnostic accuracy","validation","prostate biopsy","primary care","implementation science","precision prevention","clinically significant prostate cancer","clinical prediction model","community oncology","NOT_YET_RECRUITING","2026-07-24",{"date":101,"type":102},"2026-07-29","ACTUAL",{"date":104,"type":61},"2029-03",{"date":106,"type":61},"2029-08",{"name":5,"class":6},1]